Patents by Inventor Steve Granger

Steve Granger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibody-fynomer conjugates
    Patent number: 10323095
    Abstract: Provided is a bi-specific fusion polypeptide comprising a fynomer sequence that binds to interleukin-17a (IL-17a) and is conjugated to an antibody or subsequence thereof that binds to interleukin-6 receptor (IL-6R). The fusion polypeptide can bind to both IL-17a and IL-6R thereby suppresses, reduces, decreases, inhibits or blocks both IL-17a and IL-6R activities.
    Type: Grant
    Filed: March 16, 2015
    Date of Patent: June 18, 2019
    Assignee: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Roland Newman, Steve Granger, Michael Lyman, Dragan Grabulovski, Richard Woods, Michela Silacci, Wenjuan Zha, Isabella Attinger-Toller
  • ANTIBODY-FYNOMER CONJUGATES
    Publication number: 20170081412
    Abstract: Provided is a bi-specific fusion polypeptide comprising a fynomer sequence that binds to interleukin-17a (IL-17a) and is conjugated to an antibody or subsequence thereof that binds to interleukin-6 receptor (IL-6R). The fusion polypeptide can bind to both IL-17a and IL-6R thereby suppresses, reduces, decreases, inhibits or blocks both IL-17a and IL-6R activities.
    Type: Application
    Filed: March 16, 2015
    Publication date: March 23, 2017
    Applicant: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Roland NEWMAN, Steve GRANGER, Michael LYMAN, Dragan GRABULOVSKI, Richard WOODS, Michela SILACCI, Wenjuan ZHA, Isabella ATTINGER-TOLLER
  • Vaccinia virus H3L and B5R specific monoclonal antibodies and methods of making and using same
    Patent number: 9447172
    Abstract: The invention relates to antibodies and subsequences thereof that specifically bind to poxvirus B5R envelope protein, antibodies and subsequences thereof that specifically bind to poxvirus H3L envelope protein, and combinations thereof.
    Type: Grant
    Filed: December 27, 2013
    Date of Patent: September 20, 2016
    Assignees: KYOWA HAKKO KIRIN CO., LTD., LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY
    Inventors: Shinichiro Kato, Steve Granger, Shane Crotty, Sandra Rickert, Lilia Koriazova, Tomoyuki Tahara
  • VACCINIA VIRUS H3L AND B5R SPECIFIC MONOCLONAL ANTIBODIES AND METHODS OF MAKING AND USING SAME
    Publication number: 20140186370
    Abstract: The invention relates to antibodies and subsequences thereof that specifically bind to poxvirus B5R envelope protein, antibodies and subsequences thereof that specifically bind to poxvirus H3L envelope protein, and combinations thereof.
    Type: Application
    Filed: December 27, 2013
    Publication date: July 3, 2014
    Applicants: LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY, KYOWA HAKKO KIRIN CO., LTD.
    Inventors: SHINICHIRO KATO, STEVE GRANGER, SHANE CROTTY, SANDRA RICKERT, LILIA KORIAZOVA, TOMOYUKI TAHARA
  • Vaccinia virus H3L and B5R specific monoclonal antibodies and methods of making and using same
    Patent number: 8623370
    Abstract: The invention relates to antibodies and subsequences thereof that specifically bind to poxvirus B5R envelope protein, antibodies and subsequences thereof that specifically bind to pox virus H3L envelope protein, and combinations thereof.
    Type: Grant
    Filed: October 6, 2008
    Date of Patent: January 7, 2014
    Assignees: Kyowa Hakko Kirin Co., Ltd., La Jolla Institute for Allergy and Immunology
    Inventors: Shinichiro Kato, Steve Granger, Shane Crotty, Sandra Rickert, Lilia Koriazova, Tomoyuki Tahara